CEO’S CORNER

The World Bank’s New Chief

The National Academies of Sciences, Engineering, and Medicine continued to accept donations from some Sackler family members, particularly those connected to Purdue Pharma, even as the country's drug crisis worsened. The National Academies of Sciences, Engineering, and Medicine, a renowned advisory organization, have been enlisted by the White House and Congress over the past ten years to help define the federal response to the opioid crisis, whether by convening expert panels or giving policy recommendations and studies.

However, National Academies o remained silent about one matter: their choice to accept around $19 million in donations from the Sackler family, who own Purdue Pharma, the company that produces the drug OxyContin, which is known for causing the opioid epidemic.The narcotic Thousands of overdose deaths have resulted from the disaster, which has also given rise to litigation and pushed other institutions to publicly separate themselves from Sackler money or disclose possible conflicts of interest resulting from connections to Purdue Pharma. The National Academies continues to advise the government on opioids while mostly avoiding such scrutiny.

The well-known pain care researcher

Presented By Kennedy Lucas Publishings LC

Michael Von Korff said, "I didn't know they were collecting private money. "Taking money from drug company executives and then publishing reports on opioids seems insane. I'm very surprised. The National Academies has not done a public review to see if the World Health Organization's two publications on opioid policy had merit, in contrast to the WHO, which was accused of being controlled by Purdue and eventually withdrew them. Despite publishing two significant findings that had a significant impact on national opioid policy, Sackler funding affected its decision-making.

One of those studies, published in 2011 and since completely debunked, estimated that 100 million Americans experienced chronic pain, but this figure turned out to be greatly exaggerated. However, it provided pharmaceutical companies with yet another talking point encouraged physicians to prescribe opioids more frequently, and led the Food and Drug approve at least one